CagriSema Dosage: Doses Studied, Units and Chart
What doses of CagriSema have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 10 studies
- with a stated dose, listed below
- Frequency
- once weekly
- as used in studies
- Half-life
- 159-195 h (with semaglutide 2.4 mg co-administered)
- subcutaneous, in people · Lancet 2021, PMID 33894838
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| cagrilintide 2.4 mg plus semaglutide 2.4 mg vs semaglutide 2.4 mg | once weekly · subcutaneous · 68 weeks | Human RCTn = 331 | The lancet. Diabetes & endocrinology 2026, PMID 42009015 |
| cagrilintide plus semaglutide, 2.4 mg each or 1.0 mg each, vs placebo | once weekly · subcutaneous · 40 weeks | Human RCTn = 189 | The lancet. Diabetes & endocrinology 2026, PMID 42251860 |
| cagrilintide plus semaglutide 2.4 mg each or 1.0 mg each, vs semaglutide, cagrilintide or placebo | once weekly · subcutaneous · 68 weeks | Human RCTn = 2713 | The lancet. Diabetes & endocrinology 2026, PMID 42251859 |
| cagrilintide plus semaglutide 2.4 mg each or 1.0 mg each, vs placebo | once weekly · subcutaneous · 40 weeks | Human RCTn = 274 | Lancet 2026, PMID 42251856 |
| CagriSema 2.4 mg/2.4 mg vs placebo (also semaglutide and cagrilintide arms) | once weekly · subcutaneous · 68 weeks | Human RCTn = 3417 | Hypertension 2026, PMID 41328546 |
| CagriSema 2.4 mg/2.4 mg vs semaglutide, cagrilintide or placebo | once weekly · subcutaneous · 68 weeks | Human controlled trial | Diabetes, obesity & metabolism 2026, PMID 42503495 |
| cagrilintide 2.4 mg plus semaglutide 2.4 mg (vs each alone or placebo) | once weekly · subcutaneous · 68 weeks | Human RCTn = 3417 | The New England journal of medicine 2025, PMID 40544433 |
| cagrilintide 2.4 mg plus semaglutide 2.4 mg vs placebo (3:1) | once weekly · subcutaneous · 68 weeks | Human RCTn = 1206 | The New England journal of medicine 2025, PMID 40544432 |
| cagrilintide 2.4 mg plus semaglutide 2.4 mg (CagriSema) vs semaglutide or cagrilintide alone | once weekly · subcutaneous · 32 weeks | Human RCTn = 92 | Lancet 2023, PMID 37364590 |
| cagrilintide 0.16-4.5 mg plus semaglutide 2.4 mg, vs placebo plus semaglutide | once weekly · subcutaneous · 20 weeks (16 weeks co-escalation, 4 weeks at target dose) | Human RCTn = 96 | Lancet 2021, PMID 33894838 |
Before anyone considers it
- CagriSema is investigational and not approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
Is CagriSema FDA approved?
No. CagriSema is investigational (investigational · filed with fda) and not approved for any use.
More on CagriSema
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
- 4Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026PMID 42251860Accessed 2 Oct 2026
- 5Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026PMID 42251859Accessed 2 Oct 2026
- 6Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet (London, England) · 2026PMID 42251856Accessed 2 Oct 2026
- 7CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) · 2026PMID 41328546Accessed 2 Oct 2026
- 8Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes, obesity & metabolism · 2026PMID 42503495Accessed 2 Oct 2026
- 9Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
- 10Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
- 11Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 2 Oct 2026
- 12Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
Found an error? Report a correction.